236 related articles for article (PubMed ID: 33649535)
21. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.
Mezzadra R; Sun C; Jae LT; Gomez-Eerland R; de Vries E; Wu W; Logtenberg MEW; Slagter M; Rozeman EA; Hofland I; Broeks A; Horlings HM; Wessels LFA; Blank CU; Xiao Y; Heck AJR; Borst J; Brummelkamp TR; Schumacher TNM
Nature; 2017 Sep; 549(7670):106-110. PubMed ID: 28813410
[TBL] [Abstract][Full Text] [Related]
22. The clinical and prognostic significance of CMTM6/PD-L1 in oncology.
Yaseen MM; Abuharfeil NM; Darmani H
Clin Transl Oncol; 2022 Aug; 24(8):1478-1491. PubMed ID: 35278198
[TBL] [Abstract][Full Text] [Related]
23. Doxorubicin inhibits PD-L1 expression by enhancing TTP-mediated decay of PD-L1 mRNA in cancer cells.
Kim DJ; Jang JH; Ham SY; Choi SH; Park SS; Jeong SY; Kim BC; Jeon DY; Lee BJ; Ko BK; Park JW; Cho WJ
Biochem Biophys Res Commun; 2020 Feb; 522(2):402-407. PubMed ID: 31767150
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
[TBL] [Abstract][Full Text] [Related]
25. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
[TBL] [Abstract][Full Text] [Related]
26. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis.
Huang Y; Xia L; Tan X; Zhang J; Zeng W; Tan B; Yu X; Fang W; Yang Z
Cell Mol Biol Lett; 2022 Jun; 27(1):43. PubMed ID: 35658874
[TBL] [Abstract][Full Text] [Related]
27. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis.
Blanco FF; Preet R; Aguado A; Vishwakarma V; Stevens LE; Vyas A; Padhye S; Xu L; Weir SJ; Anant S; Meisner-Kober N; Brody JR; Dixon DA
Oncotarget; 2016 Nov; 7(45):74043-74058. PubMed ID: 27677075
[TBL] [Abstract][Full Text] [Related]
28. Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer.
Nishi M; Shimada M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Eto S; Yoshimoto T
J Med Invest; 2021; 68(3.4):362-367. PubMed ID: 34759159
[TBL] [Abstract][Full Text] [Related]
29. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
[TBL] [Abstract][Full Text] [Related]
30. Posttranscriptional regulation of IL-13 in T cells: role of the RNA-binding protein HuR.
Casolaro V; Fang X; Tancowny B; Fan J; Wu F; Srikantan S; Asaki SY; De Fanis U; Huang SK; Gorospe M; Atasoy UX; Stellato C
J Allergy Clin Immunol; 2008 Apr; 121(4):853-9.e4. PubMed ID: 18279945
[TBL] [Abstract][Full Text] [Related]
31. CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1.
Zeisbrich M; Chevalier N; Sehnert B; Rizzi M; Venhoff N; Thiel J; Voll RE
Front Immunol; 2021; 12():673912. PubMed ID: 34108971
[TBL] [Abstract][Full Text] [Related]
32. Interaction between 3' untranslated region of calcitonin receptor messenger ribonucleic acid (RNA) and adenylate/uridylate (AU)-rich element binding proteins (AU-rich RNA-binding factor 1 and Hu antigen R).
Yasuda S; Wada S; Arao Y; Kogawa M; Kayama F; Katayama S
Endocrinology; 2004 Apr; 145(4):1730-8. PubMed ID: 14715706
[TBL] [Abstract][Full Text] [Related]
33. TERC suppresses PD-L1 expression by downregulating RNA binding protein HuR.
Jin H; Chen Y; Ren J; Huang J; Zhao Y; Liu H
Sci China Life Sci; 2022 Dec; 65(12):2505-2516. PubMed ID: 35661964
[TBL] [Abstract][Full Text] [Related]
34. CMTM6 recruits T cells within the endocervical adenocarcinoma microenvironment and suppresses cell proliferation via the p53 pathway.
Liang HY; Chen SL; Cai SH; Zhang SW; Yang X; Wei LJ; Luo RZ; Liu LL
J Med Virol; 2023 Mar; 95(3):e28605. PubMed ID: 36815510
[TBL] [Abstract][Full Text] [Related]
35. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Kataoka K; Shiraishi Y; Takeda Y; Sakata S; Matsumoto M; Nagano S; Maeda T; Nagata Y; Kitanaka A; Mizuno S; Tanaka H; Chiba K; Ito S; Watatani Y; Kakiuchi N; Suzuki H; Yoshizato T; Yoshida K; Sanada M; Itonaga H; Imaizumi Y; Totoki Y; Munakata W; Nakamura H; Hama N; Shide K; Kubuki Y; Hidaka T; Kameda T; Masuda K; Minato N; Kashiwase K; Izutsu K; Takaori-Kondo A; Miyazaki Y; Takahashi S; Shibata T; Kawamoto H; Akatsuka Y; Shimoda K; Takeuchi K; Seya T; Miyano S; Ogawa S
Nature; 2016 Jun; 534(7607):402-6. PubMed ID: 27281199
[TBL] [Abstract][Full Text] [Related]
36. The AU-rich element landscape across human transcriptome reveals a large proportion in introns and regulation by ELAVL1/HuR.
Bakheet T; Hitti E; Al-Saif M; Moghrabi WN; Khabar KSA
Biochim Biophys Acta Gene Regul Mech; 2018 Feb; 1861(2):167-177. PubMed ID: 29413897
[TBL] [Abstract][Full Text] [Related]
37. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence.
Muranushi R; Araki K; Yokobori T; Chingunjav B; Hoshino K; Dolgormaa G; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Harimoto N; Shimoda Y; Sano R; Oyama T; Saeki H; Shirabe K
Cancer Sci; 2021 Aug; 112(8):3314-3323. PubMed ID: 34080242
[TBL] [Abstract][Full Text] [Related]
38. IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3' untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR.
Suswam EA; Nabors LB; Huang Y; Yang X; King PH
Int J Cancer; 2005 Mar; 113(6):911-9. PubMed ID: 15514971
[TBL] [Abstract][Full Text] [Related]
39. What does PD-L1 positive or negative mean?
Ribas A; Hu-Lieskovan S
J Exp Med; 2016 Dec; 213(13):2835-2840. PubMed ID: 27903604
[TBL] [Abstract][Full Text] [Related]
40. CMTM6: increased circulating level and up-regulated expression in labial salivary glands in patients with primary Sjogren's syndrome.
Qian S; Xu J; Zhao S; Yang P; Yang C
Clin Exp Immunol; 2022 Jan; 207(1):65-71. PubMed ID: 35020842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
